Therapeutic hypothermia for acute myocardial infarction and cardiac arrest

Bryan G Schwartz1, Robert A Kloner, Joseph L Thomas

  • 1Heart Institute, Good Samaritan Hospital, Los Angeles, CA, USA.

Insights

Therapeutic hypothermia (TH) improves survival for cardiac arrest patients. Rapid TH induction benefits ST-elevation myocardial infarction (STEMI) patients, but methods require further study for optimal outcomes.

Area of Science:

  • Cardiology
  • Neurology
  • Critical Care Medicine

Background:

  • Therapeutic hypothermia (TH) is a recommended intervention for cardiac arrest and ST-segment elevation myocardial infarction (STEMI).
  • Existing guidelines recommend TH for cardiac arrest resuscitation.
  • TH demonstrates significant infarct size reduction in animal models, emphasizing the importance of pre-reperfusion temperature achievement.

Purpose of the Study:

  • To review the advantages and disadvantages of various therapeutic hypothermia induction methods.
  • To assess the neuroprotective and cardioprotective benefits of TH in cardiac arrest and STEMI.
  • To explore novel TH induction techniques, including transcoronary methods.

Main Methods:

  • Review of current literature on therapeutic hypothermia induction and maintenance.
  • Comparison of surface cooling, endovascular catheters, and intravenous cold fluid infusion.
  • Discussion of emerging technologies like transcoronary TH induction.

Main Results:

  • Slow TH induction shows improved survival and neurologic outcomes in out-of-hospital cardiac arrest.
  • Rapid TH induction may offer modest neurologic benefits in cardiac arrest.
  • Rapid TH initiation in STEMI is challenging but achievable, with potential for significant infarct reduction.

Conclusions:

  • Widespread TH use can enhance survival and quality of life for cardiac arrest survivors.
  • Further research is needed on rapid TH induction methods, particularly for STEMI patients.
  • Novel methods like transcoronary TH warrant additional investigation for targeted hypothermic reperfusion.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by sustained extreme cold exposure, and severe...
Methods of reducing fever01:22

Methods of reducing fever

The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...